"Emerging wet AMD therapies including Fovista and abicipar pegol (Allergan/Molecular Partners) will need to be priced competitively to Eylea and Lucentis in order to garner favorable tier placement.
Regeneron Pharmaceuticals REGN announced that it has met the primary endpoint in a late-stage study evaluating Eylea HD (aflibercept) Injection 8 mg to treat patients with macular edema following ...
Regulatory agreement of using Lucentis ® and Eylea ® in combination with OPT-302 across two pivotal Phase 3 trials increases the potential multi-billion dollar market opportunity Lucentis ® and Eylea ...
May 1 (Reuters) - Allergan Inc said approval of its Darpin eye drug could be delayed up to two years, providing a new boost to Regeneron Pharmaceuticals Inc whose successful treatment, Eylea, stands ...
The primary endpoint of the study, known as RIDE, showed that after 24 months a significantly greater number of patients who received Lucentis, compared to those who received placebo (sham) injections ...
People with proliferative diabetic retinopathy may develop another eye condition called macular edema. The macula is the part of the retina that processes the images in the center of your vision ...
Opthea is a clinical-stage biotech firm developing Sozinibercept, targeting VEGF-C and VEGF-D for wet AMD, with Phase 3 results due in 2025. The wet AMD market is lucrative, but the challenge lies in ...
The U.S. government is accusing Regeneron of deliberately using an unusual method to overcharge Medicare for the company’s popular eye drug Eylea. In a lawsuit filed with the U.S. District Court in ...
EyePoint is a $200m market cap biotech focused on eye disease. The company's long-acting Durasert technology has been supporting its commercial product, YUTIQ, which earned $28m of revenues in FY22.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback